In: Vaccines, 2021, vol. 9, no. 9, p. 7
Since marketing authorization, cases of neuralgic amyotrophy (NA), facial paralysis/Bell’s palsy (FP/BP), and Guillain-Barré syndrome (GBS) were reported with COVID-19 vaccines of different technologies. This study aimed to assess whether NA, FP/BP, and GBS were more frequently reported in VigiBase with COVID-19 vaccines (of any technologies) than with other viral vaccines, over the full...
|
In: Cancers, 2020, vol. 12, no. 11, p. 15
Up to 50% of myocarditis events developed in cancer patients upon treatment with immune checkpoint inhibitors (ICIs) are fatal. Therefore, identification of clinical risk factors predicting myocarditis onset during treatment with ICIs is important for the purpose of cardiac surveillance of high-risk patients. The aim of this retrospective matched case-control study was to assess whether...
|
In: European Journal of Clinical Pharmacology, 2015, vol. 71, no. 2, p. 209-217
|
In: European Child & Adolescent Psychiatry, 2015, vol. 24, no. 6, p. 635-640
|
In: European Journal of Pediatrics, 2015, vol. 174, no. 10, p. 1347-1355
|
In: Journal of Antimicrobial Chemotherapy, 2019, vol. 74, no. 6, p. 1521–1530
Beyond plasmid-encoded resistance (mcr genes) prevalence in strain collections, large epidemiological studies to estimate the human burden of colistin-resistant Escherichia coli gut carriage are lacking.Objectives: To evaluate the prevalence of colistin-resistant E. coli carriage in inpatients and decipher the molecular support of resistance and the genetic background of the strains.Methods:...
|
In: World Journal of Surgery, 2013, vol. 37, no. 9, p. 2162-2171
|
In: Infection, 2003, vol. 31, no. 6, p. 398-403
|
In: Cardiovascular Drugs and Therapy, 2005, vol. 19, no. 4, p. 291-299
|
In: Supportive Care in Cancer, 2012, vol. 20, no. 3, p. 575-581
|